Literature DB >> 30159602

Optical coherence tomography angiography for screening of hydroxychloroquine-induced retinal alterations.

Mehmet Bulut1, Melih Akıdan2, Onursal Gözkaya3, Muhammet Kazım Erol2, Ayşe Cengiz2, Hasan Fatih Çay4.   

Abstract

BACKGROUND/AIMS: The purpose of the study was to evaluate the retinal and choroidal changes via optical coherence tomography angiography (OCTA) in patients who received hydroxychloroquine (HCQ).
METHODS: Sixty eyes of 60 female patients who received HCQ were included in the study. Patients were categorized into two groups as high-risk (≥ 5 years) and low-risk (< 5 years) in terms of HCQ-induced retinal toxicity. Spectral domain-OCT, OCTA, and visual field tests were performed. Retinal thickness, vascular density, flow rates, choroidal thickness (CT), and visual field parameters were compared between the groups, and the correlation between total HCQ cumulative dose, duration of use, and these parameters was assessed.
RESULTS: Compared to low-risk group, patients in the high-risk group had vascular density loss (p < 0.05). In this group, foveal avascular zone (FAZ) was found to be wider (p < 0.05). Retinal and choroidal flow rates were found to be decreased markedly in the high-risk group (p < 0.05). CT was found to be thinner in the high-risk group (p < 0.05). HCQ cumulative dose and duration of use had a negative significant correlation with all vascular density, flow rate, CT parameters, and positive significant correlation with FAZ parameters (p < 0.05). In visual field tests, mean defect (MD) was found to be increased in the high-risk group (p < 0.05). Moreover, MD had a positive correlation with HCQ cumulative dose and duration of use (p < 0.05).
CONCLUSIONS: Evaluation of microvascular changes via OCTA may contribute to the early detection of HCQ-induced retinal toxicity, which cannot be detected through other imaging devices, at the stage when it is reversible.

Entities:  

Keywords:  Hydroxychloroquine; Optical coherence tomography angiography (OCTA); Retina; Toxicity

Mesh:

Substances:

Year:  2018        PMID: 30159602     DOI: 10.1007/s00417-018-4117-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  23 in total

Review 1.  Optical coherence tomography angiography in chorioretinal disorders.

Authors:  Paulo Ricardo Chaves De Oliveira; Alan Richard Berger; David Robert Chow
Journal:  Can J Ophthalmol       Date:  2016-11-28       Impact factor: 1.882

Review 2.  The application of optical coherence tomography angiography in retinal diseases.

Authors:  Kumar Sambhav; Sandeep Grover; Kakarla V Chalam
Journal:  Surv Ophthalmol       Date:  2017-06-01       Impact factor: 6.048

3.  Optical Coherence Tomography Angiography of the Peripapillary Retina in Glaucoma.

Authors:  Liang Liu; Yali Jia; Hana L Takusagawa; Alex D Pechauer; Beth Edmunds; Lorinna Lombardi; Ellen Davis; John C Morrison; David Huang
Journal:  JAMA Ophthalmol       Date:  2015-09       Impact factor: 7.389

4.  Spectral domain optical coherence tomography detects early stages of chloroquine retinopathy similar to multifocal electroretinography, fundus autofluorescence and near-infrared autofluorescence.

Authors:  S Kellner; S Weinitz; U Kellner
Journal:  Br J Ophthalmol       Date:  2009-08-18       Impact factor: 4.638

Review 5.  Hydroxychloroquine retinopathy.

Authors:  I H Yusuf; S Sharma; R Luqmani; S M Downes
Journal:  Eye (Lond)       Date:  2017-03-10       Impact factor: 3.775

6.  Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).

Authors:  Michael F Marmor; Ulrich Kellner; Timothy Y Y Lai; Ronald B Melles; William F Mieler
Journal:  Ophthalmology       Date:  2016-03-16       Impact factor: 12.079

7.  Choroidal Thinning Associated With Hydroxychloroquine Retinopathy.

Authors:  Seong Joon Ahn; So Jung Ryu; Joo Young Joung; Byung Ro Lee
Journal:  Am J Ophthalmol       Date:  2017-09-08       Impact factor: 5.258

8.  Scotoma analysis of 10-2 visual field testing with a red target in screening for hydroxychloroquine retinopathy.

Authors:  David J Browning; Chong Lee
Journal:  Clin Ophthalmol       Date:  2015-08-20

9.  Retinal vessel density from optical coherence tomography angiography to differentiate early glaucoma, pre-perimetric glaucoma and normal eyes.

Authors:  Handan Akil; Alex S Huang; Brian A Francis; Sirinivas R Sadda; Vikas Chopra
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

10.  A New Objective Parameter in Hydroxychloroquine-Induced Retinal Toxicity Screening Test: Macular Retinal Ganglion Cell-Inner Plexiform Layer Thickness.

Authors:  Mehmet Bulut; Muhammet Kazım Erol; Devrim Toslak; Melih Akidan; Ebru Kaya Başar; Hasan Fatih Çay
Journal:  Arch Rheumatol       Date:  2017-10-16       Impact factor: 1.472

View more
  4 in total

Review 1.  [Progressive maculopathy despite discontinuation of chloroquine treatment-multimodal imaging and review of the literature].

Authors:  A Rickmann; S Al-Nawaiseh; L Ramirez; S Röhrig; M Ladewig; P Szurman; G Szurman
Journal:  Ophthalmologe       Date:  2020-09       Impact factor: 1.059

Review 2.  Optical coherence tomography angiography-derived flow density: a review of the influencing factors.

Authors:  Viktoria C Brücher; Jens J Storp; Nicole Eter; Maged Alnawaiseh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-12-09       Impact factor: 3.117

3.  Evaluation of optical coherence tomography angiography parameters in patients treated with Hydroxychloroquine.

Authors:  Mohammadreza Akhlaghi; Farzan Kianersi; Hamed Radmehr; Alireza Dehghani; Afsaneh Naderi Beni; Pegah Noorshargh
Journal:  BMC Ophthalmol       Date:  2021-05-11       Impact factor: 2.209

4.  Altered microvascular density in patients with systemic lupus erythematosus treated with hydroxychloroquine-an optical coherence tomography angiography study.

Authors:  Nataša Mihailovic; Martin Dominik Leclaire; Nicole Eter; Viktoria C Brücher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-06-12       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.